CRISPR And Cas Genes Market To Reach $9.61 Billion By 2030

CRISPR And Cas Genes Market Growth & Trends

The global CRISPR and Cas genes market size is expected to reach USD 9.61 billion by 2030, growing at a CAGR of 17.15% from 2023 to 2030, according to a new report by Grand View Research, Inc. The use of CRISPR-Cas systems in diagnostics and the assessment of evolutionary analysis in prokaryotes has significantly increased, owing to the developments in the field of genome editing. The application of this technology enables easy and cost-efficient editing of genes. Genome editing has made a significant advancement in biomedical research, with the present trend of cutting-edge techniques paving the way for the future treatment of different genetic and non-genetic disorders.

The development and implementation of more effective ways for gene targeting and the generation of gene-edited avian species have been facilitated by the availability of the CRISPR/Cas9-mediated gene and genome editing technology. According to an article published on Frontiers in February 2021, CRISPR/Cas9 has become a robust and important tool for gene editing in the poultry industry. Potential applications in several fields would further boost the demand for this technology. The COVID-19 outbreak shifted the researcher’s emphasis to the development of COVID-19 molecular diagnostic tools based on this technology. For instance, in March 2021, Nanyang Technological University researchers in Singapore created a COVID-19 test based on CRISPR that provides results in 30 minutes.

Even after the virus has mutated, this test still discovers it. This would further encourage the other key players to leverage this technique, thereby driving the industry's growth. This technology is increasingly being used for several medical and other applications. Competition over patents for such a gene-editing technology is expected to grow, as more academic institutions and biotech companies attempt to develop new commercial applications of this technology. In addition, there is a lot of potential for this technique to advance with the use of machine learning technologies. For instance, in August 2022, Synthego launched engineered cell libraries, a cutting-edge service that expands access to CRISPR by giving arrayed CRISPR-edited cells for use directly in functional screening experiments.

It has potential applications in disease research. Key players offer tools and solutions for each step of the gene editing workflow. Integrating several tools, services, and improved processes makes it possible to complete research experiments rapidly and with little effort. Moreover, key players have raised significant funding to support the R&D of the CRISPR & Cas9 gene-editing approach. For instance, in April 2021, Vertex Pharmaceuticals collaborated with CRISPR Therapeutics to develop and manufacture a new CRISPR/Cas9-based gene editing therapy called CTX001, a potential therapeutic option for transfusion-dependent beta-thalassemia and Sickle Cell Disease (SCD). In January 2020, Mammoth Biosciences raised USD 45 million to develop next-gen CRISPR products for therapeutics & diagnostics purposes. This would further be used to develop the company’s CRISPR genes-driven diagnostics portfolio.

 Request a free sample copy or view report summary: CRISPR And Cas Genes Market Report

CRISPR And Cas Genes Market Report Highlights

• By product and services, the product segment dominated the industry in 2022 and accounted for the highest share of 78.86%

• The biomedical segment dominated the industry in 2022. Extensive research and a significant rise in the number of research studies utilizing the advanced technique for genome editing have contributed to the segment growth

• The biotechnology and pharmaceutical companies dominated the market in 2022, accounting for 49.68% of overall revenue share. Key players are adopting this technology to produce biological models for human diseases and further accelerate new therapeutic target identification

• North America dominated the market and accounted for the highest revenue share of 38.37% in 2022 owing to the presence of several pharmaceutical giants, increased research funding, a high number of research approvals, and the need for novel therapeutics

CRISPR And Cas Genes Market Segmentation

Grand View Research has segmented the global CRISPR and Cas genes market based on product & service, application, end-use, and region: 

CRISPR And Cas Genes Product & Service Outlook (Revenue, USD Million, 2018 - 2030)

• By Product

  • Kits & Enzymes

    • Vector-based Cas

    • DNA-free Cas

  • Libraries

  • Design Tool

  • Antibodies

  • Others

• By Service

  • Cell Line Engineering

  • gRNA Design

  • Microbial Gene Editing

  • DNA Synthesis

CRISPR And Cas Genes Application Outlook (Revenue, USD Million, 2018 - 2030)

• Biomedical

  • Genome Engineering

  • Disease Model Studies

  • Functional Genomics

  • Epigenetics

  • Others

• Agricultural

CRISPR And Cas Genes End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Biotechnology & Pharmaceutical Companies

• Academics & Government Research Institutes

• Contract Research Organizations (CROs)

CRISPR And Cas Genes Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • Germany

  • France

  • Italy

  • Spain

  • U.K.

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • China

  • Japan

  • India

  • South Korea

  • Thailand

  • Australia

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players of CRISPR And Cas Genes Market

• AstraZeneca plc

• Addgene

• Caribou Biosciences, Inc.

• Cellectis, CRISPR Therapeutics

• Editas Medicine, Inc.

• eGenesis

• F. Hoffmann-La Roche Ltd.

• Horizon Discovery Group plc

• GenScript

• Danaher Corp.

• Intellia Therapeutics, Inc.

• Lonza

• Merck KGaA

• Intellia Therapeutics, Inc.

• Takara Bio Inc.

• Thermo Fisher Scientific, Inc.

• Synthego

• Mammoth Biosciences

• Inscripta, Inc.

• Cibus

• Beam Therapeutics

• PLANTeDIT

• Vertex Pharmaceuticals Inc.

• Hera BioLabs

• OriGene Technologies, Inc.

• Recombinetics, Inc.